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Abstract 
Multiple myeloma (MM) remains a largely incurable disease in the long term despite 
positive responses to first-line chemotherapy. Herein we report the case of a 68-year-old 
woman who died following treatment with bortezomib plus dexamethasone for 
refractory MM. The combination was associated with significant antitumor activity, but 
bacterial pneumonia/sepsis was followed by bilateral cytomegalovirus pneumonia with 
herpes simplex co-infection, and this was almost certainly the cause of death. Physicians 
need to pay careful attention when treating patients with refractory MM with 
bortezomib plus dexamethasone, and to be mindful that antiviral therapy may be 
needed in some cases. 
 
Multiple myeloma (MM) is still largely incurable despite continued intensive efforts. 
Following recent advances in terms of treatment options, patients generally respond to 
first-line chemotherapy; however, the majority will experience relapse or become 
refractory to therapy. Bortezomib, the first-in-class proteasome inhibitor, has been shown 
to have significant antitumor activity in the treatment of relapsed/refractory patients with 
MM [1, 2]. The most common adverse events with bortezomib reported to date include  
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gastrointestinal symptoms, fatigue, thrombocytopenia, and peripheral neuropathy [1, 2]. 
The main dose-limiting toxicity associated with bortezomib therapy is peripheral 
neuropathy [3]. Here we report a relapsed/refractory MM case with severe 
cytomegalovirus (CMV) and herpes virus (HSV) coinfection after bortezomib therapy. In 
this patient, bortezomib produced a significant antimyeloma effect, but CMV was 
detected in multiple organs and HSV-induced esophagitis was also observed. CMV 
pneumonia and bilateral diffuse alveolar damage led to death. 
The female patient was diagnosed with MM (IgG, λ light-chain isotype, stage IIIA) in 
August 2006 at the age of 68. Multiple compression fractures of the lumbar spine and 
extensive destruction of the iliac bones were observed. Due to these bone lesions, the 
patient was unable to stand on her own. Two courses of VAD therapy (dexamethasone 40 
mg/day on days 1–4, 9–12, and 17–20, doxorubicin 9 mg/m
2/day on days 1–4, vincristine 
0.4 mg/day on day 1–4) were administered. The chemotherapy was effective and the 
patient was discharged in December 2006. After rehabilitation to help with her walking, 
the patient was treated with MP therapy (melphalan 8 mg/m
2/day on days 1–4, 
prednisolone 60 mg/m
2/day on days 1–4) as an outpatient, from May 2007 to December 
2007. However, the left mandibular bone and its surrounding tissues became increasingly 
swollen with myeloma from late December 2007. When the patient visited our hospital in 
January 2008, a bulky mass had formed in her jaw and its surroundings. A total of 40 Gy 
of radiation therapy plus dexamethasone therapy (40 mg/day on days 1–4, 9–12, 17–20) 
was administered, but only a partial response was achieved, and the patient’s general 
condition gradually worsened. 
Both the patient and her family refused treatment with thalidomide. In March 2008, 
bortezomib 1 mg/m
2 was injected intravenously on days 1 and 8 and this was 
administered in combination with dexamethasone therapy. However, an aggressive 
increase of M protein was observed and it was thought possible that clonal evolution was 
occurring. We considered the patient to have progressive disease, and selected an 
EPOCH-like regimen (etoposide 50 mg/m
2/day on days 1–4, vincristine 0.4 mg/m
2/day 
on days 1–4, doxorubicin 10 mg/m
2/day on days 1–4, prednisolone 60 mg/m
2/day on days 
1–6) as salvage chemotherapy in April 2008. This proved to be ineffective and computed 
tomography and magnetic resonance imaging revealed the formation of a huge mass from 
the upper abdomen to the pelvic cavity (fig. 1a), together with multiple bone lesions and 
multiple intra-muscular lesions. 
In May 2008, a second course of bortezomib therapy (1 mg/m
2, by intravenous 
injection on days 1, 4, and 8) was administered together with dexamethasone therapy, and 
a reduction in M protein was observed. However, high fever and bilateral pneumonia 
occurred late in May 2008, after the chemotherapy. Coagulase-negative staphylococci 
were detected in a pharyngeal culture specimen and Staphylococcus epidermidis was 
detected in a venous blood culture specimen. Serum β-D glucan was 5.62 pg/ml. 
Examination for viral infection was not performed. Adequate antibiotics and antifungal 
agents were used to treat the pneumonia and sepsis, but antiviral agents were not used. 
The patient’s general condition worsened rapidly and she died as a result of respiratory 
failure early in June 2008. 
Post-mortem examination revealed that the two courses of therapy with bortezomib 
plus dexamethasone had been quite effective at reducing MM tumor burden. No trace of 
bacterial pneumonia was found, but CMV was detected in both lungs in conjunction with 
severe diffuse alveolar damage (fig. 1b, c). CMV was also detected in the spleen and both 
adrenal glands (data not shown). In addition to CMV infection, HSV was found to have  
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caused esophagitis (fig. 1d). Pathologically, the cause of death was diagnosed as bilateral 
CMV pneumonia with severe diffuse alveolar damage. 
To our knowledge, there has been no report of CMV and HSV coinfection in patients 
treated with bortezomib. It has been reported that bortezomib inhibits T-cell function in a 
dose-dependent manner and can reduce the ability to react to both viruses and bacteria, 
resulting in an increased risk of infection during the drug administration period [4]. In 
this patient, severe lymphopenia occurred after the first session of bortezomib plus 
dexamethasone therapy and continued until the end. Both reduced T-cell function and 
severe lymphopenia caused by bortezomib plus dexamethasone therapy might have 
enabled severe CMV and HSV coinfection to develop in this patient. 
In conclusion, bortezomib in combination with dexamethasone demonstrated 
significant antitumor activity in this relapsed and refractory myeloma patient. However, 
bacterial pneumonia, sepsis, and fatal viral infections occurred. Bilateral CMV 
pneumonia probably triggered death. Careful attention and countermeasures against viral 
infections might be needed during therapy with bortezomib plus dexamethasone. 
 
 
 
 
 
Fig. 1. a Computed tomography image of huge intra-pelvic tumor composed of myeloma cells. b CMV 
infection in the lung. Arrows indicate inclusion bodies (hematoxylin and eosin; ×200). c CMV infection 
in the lung. CMV antigens are positively stained (immunohistochemical staining; ×200). d HSV-
induced esophagitis. HSV antigens are positively stained (immunohistochemical staining; ×200). 
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